Utah Valley University has launched the Fast Track 1-2-3 program, an initiative designed to help students complete ...
Dyne Therapeutics announces FDA Fast Track designation for DYNE-101, targeting myotonic dystrophy type 1 with potential accelerated approval in 2026. Dyne Therapeutics has announced that its ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results